Campbell Newman Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Campbell Newman Asset Management's VRTX Position: Q2 2026 in Review
Campbell Newman Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 0.31% in Q2 2026, selling an estimated $2.22K and leaving 1,617 shares worth $803K. The position accounts for 0.06% of the portfolio, ranked #82.
Campbell Newman Asset Management first reported a position in VRTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $828K in Q2 2024. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Campbell Newman Asset Management held 1,617 shares of Vertex Pharmaceuticals worth $803K as of Q2 2026.
- Campbell Newman Asset Management sold 5 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.22K.
- Vertex Pharmaceuticals made up 0.06% of Campbell Newman Asset Management's portfolio in Q2 2026, its #82 holding.
- Campbell Newman Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
- Campbell Newman Asset Management's Vertex Pharmaceuticals position peaked at $828K in Q2 2024.
- 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Campbell Newman Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.